MannKind Corporation (MNKD) Bulls Bet On a Bigger Bounce

MannKind Corporation (MNKD) is one of several pharma stocks on the move

Digital Content Group
Mar 10, 2015 at 2:27 PM
facebook twitter linkedin


It's been an eventful day for pharmaceutical stocks, with a number of names making big moves -- including MannKind Corporation (NASDAQ:MNKD). At last check, the shares were up 3.2% at $5.51. Turning to the options pits, a number of traders are wagering on additional upside for the equity.

MNKD's most active option by a mile is the in-the-money May 5 call. All signs point to buy-to-open activity, and based on the volume-weighted average price (VWAP) of $0.67, the speculators expect the stock will land above breakeven at $5.67 (strike plus VWAP) at the close on Friday, May 15 -- when the option expires.

Today's focus on calls represents a change of pace for MNKD. The equity's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.67 ranks in the 76th percentile of its annual range. Similarly, MNKD's Schaeffer's put/call open interest ratio (SOIR) of 0.84 outstrips 73% of all comparable readings from the last year.

One group that's likely unhappy with MannKind Corporation's (NASDAQ:MNKD) intraday gains is short sellers. Roughly one-third of the stock's float is dedicated to short interest, representing 9.3 times the equity's daily trading volume.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners